Want to see AU:ALA full AI Analyst Report?
Top Page
Arovella Therapeutics Limited
(Sydney:ALA)
Select Model
Select Model
Rating:41Neutral
Price Target:
AU$0.05
▼(-15.00% Downside)
Action:Reiterated
Date:09/29/26
The score is primarily weighed down by weak financial performance (minimal/unstable revenue, ongoing losses, and continued cash burn). Technicals further detract due to a clear downtrend and bearish momentum signals. Valuation offers limited support because the company is loss-making (negative P/E) and there is no dividend yield data.
Positive Factors
Cell therapy development focus
A focused pipeline in engineered immune-cell therapies gives Arovella a defined scientific direction in cancer treatment development. CAR and related platform work could support differentiated clinical programs if the technologies demonstrate improved targeting and potency.
Negative Factors
No scalable commercial revenue
Zero revenue confirms that Arovella has not yet established a scalable commercial base and remains dependent on development progress rather than operating sales. Without recurring product income, future programs must continue to create value before the business can fund itself internally.
Read all positive and negative factors
Positive Factors
Negative Factors
Cell therapy development focus
A focused pipeline in engineered immune-cell therapies gives Arovella a defined scientific direction in cancer treatment development. CAR and related platform work could support differentiated clinical programs if the technologies demonstrate improved targeting and potency.
Read all positive factors
Arovella Therapeutics Limited (ALA) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$61.65M
Dividend YieldN/A
Average Volume (3M)935.54K
Price to Earnings (P/E)―
Beta (1Y)1.49
Revenue Growth-100.00%
EPS Growth14.71%
CountryAU
Employees27
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,208,851,800
10 Day Avg. Volume905,107
30 Day Avg. Volume935,540
Financial Highlights & Ratios
PEG Ratio0.73
Price to Book (P/B)5.26
Price to Sales (P/S)0.00
P/FCF Ratio-10.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Arovella Therapeutics Limited Business Overview & Revenue Model
Company Description
Arovella Therapeutics Limited, an Australian biotechnology firm, is dedicated to developing therapeutic solutions for oncology and central nervous system afflictions, operating both domestically and internationally. Its pipeline features several k...
Arovella Therapeutics Limited Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
28
Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 136.00K | 17.00K | 405.90K | 295.81K |
| Gross Profit | -117.71K | 136.00K | -25.98K | -3.00M | 88.75K |
| EBITDA | -11.10M | -11.10M | -10.63M | -10.37M | -7.87M |
| Net Income | -6.92M | -7.51M | -8.75M | -10.18M | -8.62M |
Balance Sheet | |||||
| Total Assets | 15.01M | 21.60M | 13.28M | 5.47M | 9.21M |
| Cash, Cash Equivalents and Short-Term Investments | 14.35M | 20.88M | 12.71M | 5.18M | 6.07M |
| Total Debt | 0.00 | 0.00 | 0.00 | 144.80K | 144.80K |
| Total Liabilities | 857.45K | 1.52M | 2.06M | 1.69M | 1.60M |
| Stockholders Equity | 14.15M | 20.08M | 11.23M | 3.78M | 7.62M |
Cash Flow | |||||
| Free Cash Flow | -6.95M | -7.34M | -7.04M | -6.40M | -6.83M |
| Operating Cash Flow | -6.91M | -6.93M | -6.91M | -6.40M | -6.27M |
| Investing Cash Flow | -40.48K | -432.11K | -179.34K | 95.42K | -566.00K |
| Financing Cash Flow | 488.69K | 15.52M | 14.61M | 5.41M | 6.19M |
Arovella Therapeutics Limited Technical Analysis
Negative
0.06
Price Trends
0.06
Negative
0.06
Negative
0.07
Negative
Market Momentum
>-0.01
Negative
38.92
Neutral
22.22
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ALA, the sentiment is Negative. The current price of 0.06 is above the 20-day moving average (MA) of 0.05, above the 50-day MA of 0.06, and below the 200-day MA of 0.07, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 38.92 is Neutral, neither overbought nor oversold. The STOCH value of 22.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:ALA.
Arovella Therapeutics Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | AU$61.77M | -7.83 | -44.93% | ― | ― | 25.27% | |
45 Neutral | AU$102.43M | -6.47 | 84.67% | ― | ― | 42.51% | |
44 Neutral | AU$33.90M | -0.43 | -98.86% | ― | ― | -27.73% | |
42 Neutral | AU$21.20M | -0.29 | -144.24% | ― | -23.82% | 12.36% | |
41 Neutral | AU$61.65M | -8.79 | -41.83% | ― | -100.00% | 14.71% | |
41 Neutral | AU$20.88M | -0.12 | -414.10% | ― | ― | -2.15% |
* Healthcare Sector Average
AU:ALA
Arovella Therapeutics Limited
0.05
-0.04
-44.32%
AU:IMU
Imugene
0.04
-0.36
-91.03%
AU:IMM
Immutep Ltd
0.02
-0.27
-92.20%
AU:PTX
Prescient Therapeutics Limited
0.05
>-0.01
-3.77%
AU:RAD
Radiopharm Theranostics Limited
0.01
-0.02
-60.00%
AU:RCE
Recce Pharmaceuticals Ltd.
0.33
-0.09
-21.69%
Arovella Therapeutics Limited Corporate Events
Arovella boosts off-the-shelf CAR-iNKT trial readiness with second clinical batch release
Oct 6, 2026
Arovella Therapeutics has manufactured and released a second clinical batch of its donor-derived CAR-iNKT therapy ALA-101, demonstrating the reproducibility and scalability of its off-the-shelf manufacturing process. Together with a planned third ...
Arovella Showcases iNKT Cell Therapy Platform at Major Cell and Gene Meeting
Oct 6, 2026
Arovella Therapeutics will present an Innovation Spotlight at the Cell and Gene Meeting on the Mesa in Phoenix, a leading global conference for the cell and gene therapy sector. The session, delivered by acting CEO Dr Nicole van der Weerden, gives...
Arovella Nears First Patient Dosing in Pivotal ALA-101 Cell Therapy Trial
Oct 1, 2026
Arovella Therapeutics is advancing an iNKT cell therapy platform aimed at treating blood cancers, solid tumours and autoimmune disease, with its lead candidate ALA-101 designed as an allogeneic CAR19-iNKT therapy targeting CD19 and CD1d. The compa...
Arovella Deepens ESG Commitment Ahead of Australia’s Sustainability Rules
Sep 16, 2026
Arovella Therapeutics has released its fifth Environmental, Social, and Governance report, underscoring its commitment to using ESG principles to build long‑term enterprise value and align with United Nations Sustainable Development Goals. T...
Arovella Sets Hybrid 2026 AGM and Shifts to Default Digital Communications
Sep 8, 2026
Arovella Therapeutics has called its 2026 Annual General Meeting for 11:00 a.m. AEDT on 4 November 2026, offering both online participation via the Automic investor portal and an in‑person option at the offices of MinterEllison in Melbourne....
Arovella Details Governance Framework in 2026 Corporate Statement
Aug 20, 2026
Arovella Therapeutics has released its Corporate Governance Statement for the year ended 30 June 2026, outlining adherence to the ASX Corporate Governance Principles and Recommendations. The document details the roles of the board and management, ...
Arovella lodges 2026 corporate governance statement and Appendix 4G
Aug 20, 2026
Arovella Therapeutics Limited, an ASX-listed biotechnology company, underscores structured governance through formal board and management roles, written agreements with directors and executives, and an online governance portal. The company highlig...
Arovella Narrows Annual Loss as Net Tangible Assets Per Share Fall
Aug 20, 2026
Arovella Therapeutics Limited reported a net loss after tax of $6.9 million for the year ended 30 June 2026, an improvement from the $7.5 million loss recorded in the prior year. The company’s revenues from ordinary activities fell to zero, ...
Arovella Issues 9.7 Million Unquoted Options Under Employee Incentive Scheme
Aug 17, 2026
Arovella Therapeutics Limited has issued 9,749,387 unquoted options under its employee incentive scheme, with various exercise prices and expiry dates, effective 17 August 2026. The move expands the company’s pool of employee equity incentiv...
Arovella outlines strategy and ALA-101 trial timeline in investor webinar
Aug 12, 2026
Arovella Therapeutics will host an investor webinar today to brief shareholders and the market on the outcomes of its recent strategic review and priorities for advancing its iNKT cell therapy platform. The session will outline near-term clinical ...
Arovella plans investor webinar ahead of first-in-human ALA-101 trial
Aug 11, 2026
Arovella Therapeutics will host an investor webinar to update shareholders and market participants on the Board’s recent strategic review and priorities for advancing its iNKT cell therapy platform. The event will outline near-term clinical ...
Arovella Advances CAR-iNKT Programs as First Human Trial Nears
Jul 27, 2026
Arovella Therapeutics reported a transformational June quarter as it moved towards first-in-human clinical evaluation of its lead CAR-iNKT therapy, ALA-101, for relapsed or refractory CD19-positive blood cancers. The company secured ethics and gov...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.